ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, bovine serum albumin; DEPCyMC, 7-O-diethyl phosphoryl 3-cyano 4-methyl 7-hydroxycoumarin; DTNB, dithio-bis-2-nitrobenzoic acid; ELISA, enzyme-linked immunosorbent assay; HDL, highdensity lipoproteins; HH, hereditary hemochromatosis; LDL, low-density lipoproteins; PBS, phosphate-buffered saline; PON1, paraoxonase-1; TBBL, 5-thiobutyl butyrolactone. This study investigates the alterations in serum PON1 status, PON1 gene polymorphisms and PON1 hepatic expression in patients with HH. We performed a case-control study in 77 patients with HH (80.5% men, 22 -70 years of age) and 408 healthy individuals (43.1% men, 26 -74 years of age).
Abstract
Hereditary hemochromatosis (HH) is characterized by accumulation of iron, oxidative stress, inflammation and fibrogenesis in liver tissue. In this setting, research on the protection afforded by intracellular antioxidants is of clinical relevance. Paraoxonase-1 (PON1) is an enzyme that degrades lipid peroxides.
This study investigates the alterations in serum PON1 status, PON1 gene polymorphisms and PON1 hepatic expression in patients with HH. We performed a case-control study in 77 patients with HH (80.5% men, 22 -70 years of age) and 408 healthy individuals (43.1% men, 26 -74 years of age).
Serum PON1 activities against different substrates and PON1 192 and PON1 55 polymorphisms were analyzed. PON1 protein expression was investigated in 20 liver biopsies. HH patients had significantly lower serum PON1 activity, which was inversely correlated with ferritin (marker of iron stores) and serum 8-isoprostane plasma concentrations (index of oxidative stress). PON1 protein expression in liver tissue was higher in patients, and showed stronger staining in hepatocytes surrounding the areas of inflammation. Our study provides preliminary evidence that PON1 may play a role in protecting against ironinduced oxidative stress in HH.
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Hereditary hemochromatosis (HH), one of the most common genetic disorders, is characterized by accumulation of iron in several tissues, but mainly in the liver (1) . Intracellular iron is stored as ferritin, to prevent the generation of reactive oxygen species. The amount of ferritin within the cell is directly related to its iron content and, in hepatocytes of patients with HH, this can reach extreme levels (2) . However, the protective capacity of ferritin is easily overwhelmed in HH; hepatic oxidative stress and fibrogenesis being characteristic of this disorder (3, 4) . In this setting, research on the liver protection by intracellular antioxidants is of clinical relevance. HH is frequently associated with mutations in the HFE gene, which cause insufficient production of hepcidin by hepatocytes. Hepcidin inhibits iron transport by binding to the iron channel ferroportin, which is located on the basolateral surface of gut enterocytes and on the plasma membrane of reticuloendothelial cells. Inhibiting ferroportin shuts off iron transport out of storage in these cells. By inhibiting ferroportin, hepcidin prevents enterocytes of the intestines from secreting iron into the hepatic portal system, thereby functionally reducing iron absorption (2, 5) . Decreased hepatic hepcidin production then results in ineffective regulation of duodenal iron absorption, excessive delivery of iron to plasma, and iron accumulation in tissues.
Paraoxonase-1 (PON1), an enzyme with lactonase and esterase activities, degrades lipid peroxides (6-8) and plays an important role in the intracellular antioxidant system (9). In mammals, PON1 gene and protein expressions are observed in many cell types (10,11) and the enzyme is found in the circulation bound to high-density lipoproteins (HDL) (12) . Importantly, the liver plays a predominant role in the synthesis of PON1. We previously by guest, on March 11, 2013 www.jlr.org Downloaded from demonstrated that serum PON1 activity is decreased in patients with chronic hepatocellular liver diseases, despite serum PON1 concentration and hepatic PON1 protein expression being increased (13) (14) (15) . More recent evidence indicates that PON1 over-expression provides protection against liver damage (16). Conversely, low PON1 levels are associated with an enhanced sensitivity to liver disease (17). PON1 levels are genetically determined and the polymorphisms Arg/Gln at position 192 (PON1 192 , with two alleles termed Q and R), and Leu/Met at position 55 (PON1 55 , with two alleles termed L and M), are strongly associated with the enzyme's activity (9). PON1 55 polymorphism indirectly influences serum PON1 activity and concentration i.e. it is in linkage disequilibrium with the PON1 -108 promoter polymorphism, the mutation really responsible for the observed changes (18).
Recently, novel assays to measure PON1 activity have been developed using 5-thiobutyl butyrolactone (TBBL) and 7-O-diethyl phosphoryl 3-cyano 4-methyl 7-hydroxycoumarin (DEPCyMC) as substrates (19). Both TBBLase and DEPCyMCase activities are highly specific to PON1. TBBL is a chromogenic lactone that resembles the most favorable PON1 lactone substrates, allowing a specific evaluation of PON1 lactonase activity.
To date, there have been no reports on PON1 activity in HH. Hence, the aim of this study was to investigate the possible alterations in serum PON1 activity, the influence of the main PON1 gene polymorphisms, and PON1 hepatic expression in HH to ascertain whether this enzyme may be involved in the pathophysiology of this disease.
by guest, on March 11, 2013 www.jlr.org

MATERIALS AND METHODS
Study participants
Patients with clinically diagnosed HH (n = 77, 80.5% men, 22 -70 years of age) were recruited from the outpatient clinics of the Department of Medicine of the Policlinico G.B. Rossi, Verona, Italy. On entry into the study, relevant data were collected from clinical records, patient interview and physical examination. A fasting blood sample was obtained from all the participants, and serum and leukocytes were stored separately at −80ºC. Frozen aliquots were sent by guest, on March 11, 2013 www.jlr.org Downloaded from from Verona (Italy) to Reus (Spain) by overnight courier in a dry-ice package.
All the participants provided fully-informed consent to participation in the study on the understanding that anonymity of all data was guaranteed. The study was approved by the Ethics Committees (Institutional Review Boards) of the participating Hospitals.
Biochemical analyses
Serum PON1 paraoxonase and arylesterase activities were determined as the rate of hydrolysis of paraoxon (22) 
PON1 genotyping
Genomic DNA was obtained from leukocytes (Puregene DNA Isolation reagent set, Gentra Systems Inc., Minneapolis, MN, USA). Polymorphisms 
PON1 immunohistochemistry in liver tissue
Hepatic PON1 expression was assessed in sections (4 µm thick) of paraffin-embedded tissue by immunohistochemistry using the anti-PON1
by guest, on March 11, 2013 www.jlr.org Downloaded from antibody, as previously described (11) . As an index of lipid peroxidation 4-hydroxy-2-nonenal (4-HNE) protein adducts were analyzed with a specific antibody purchased from the Japan Institute for the Control of Ageing (Shizuoka, Japan). Monocyte chemoattractant protein-1 (MCP-1) expression as a marker of inflammation (27), and β-actin as a hepatic housekeeping protein (28), were measured by immunohistochemistry using specific antibodies (Santa Cruz Biotechnology Inc. Santa Cruz, CA). Five biopsies of commercial normal human liver tissue (ProteoGenex, Inc., Culver City, CA) were analyzed as controls.
Statistical analyses
All the calculations were performed with SPSS 18.0 statistical package (SPSS Inc., Chicago, IL, USA). Normality of distributions was determined with the Kolmogorov-Smirnov test. Differences between two groups were assessed with the Student's t-test (parametric) or the Mann-Whitney U test (nonparametric). Spearman correlation coefficients were used to evaluate the degree of association between variables. Qualitative data were analyzed with the χ 2 test. A multiple logistic regression model was fitted to evaluate the variables that were independently associated with HH. Results are shown as medians and 95%CI. A value of P < 0.05 was considered statistically significant.
RESULTS
Relationship between serum PON1-related variables and other biochemical indices
Demographic and biochemical variables are summarized in Table 1 . HH patients were considered as a whole, or segregated into two subgroups with respect to a history of previous phlebotomy therapy. As expected, patients with HH had significantly higher serum iron and ferritin concentrations, higher transferrin saturation, and lower serum transferrin concentrations than the control group. They also had slight, but significant, increases in serum AST and ALT activities, and a marked increase in serum 8-isoprostane concentrations.
There were weak, but significant, inverse correlations between this parameter and arylesterase activity (r = − 0.19; P = 0.001), DEPCyMCase activity (r = − 0.17; P = 0.005), and paraoxonase activity (r = − 0.012; P = 0.025) when all the participants were considered together (n = 485). HDL cholesterol concentrations were significantly lower in HH patients, as was apolipoprotein A-I, albeit this latter parameter decreased only slightly. Serum PON1
paraoxonase, arylesterase and DEPCyMCase activities were significantly decreased. HH patients with a previous history of phlebotomy were found to have lower ferritin concentrations than those without such a history, while no other parameters -including PON1 data -were significantly different between these subgroups. Moreover, in HH patients, there were highly significant associations between the four enzyme activities of PON1 (Fig. 1) .
We observed, in all of the hemochromatosis patients, relatively weak associations between arylesterase activity and transferrin (r = 0.357; P = 0.004), and between DEPCyMCase activity and transferrin saturation (r = − 0.263; P = 0.042). However, after exclusion of the 21 patients who, at the time of enrolment, were receiving phlebotomy treatment, stronger associations were found between serum iron status markers and PON1 TBBLase, and by guest, on March 11, 2013 www.jlr.org
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DEPCyMCase activities (Fig. 2) . Serum paraoxonase activity was negatively associated with ferritin (r = − 0.322; P = 0.019). On including all the iron status markers in linear regression models with the different PON1 activities as dependent variable, only ferritin remained a significant predictor of PON1 activities (data not shown).
Interestingly, and consistent with the above-mentioned results, among patients without a history of phlebotomy therapy, the C282Y homozygous 
PON1 genotyping
The Table 2 ).
Immunochemical analysis of hepatic PON1 protein expression
Representative examples of PON1 protein expression in normal livers and hepatic biopsies from patients with hemochromatosis are shown in Fig. 4 .
We observed a stronger anti-PON1 staining in hepatocytes of the patients' liver tissues than in the samples from normal subjects. We observed differences in 
DISCUSSION
The present study shows that hepatic PON1 protein expression is clearly increased in HH patients. Oxidative stress is a key feature of HH (3, 4, 29) .
PON1 is able to hydrolyze a great variety of substrates by means of its esterase and lactonase activities, and considerable evidence suggests that its physiological role is the intra-and extra-cellular hydrolysis of lipid peroxides and, thereby, playing an antioxidant role (6-9). Our results show a strong PON1 staining in the cytoplasm of hepatocytes while nuclei were not stained.
Expression was stronger in areas surrounding inflammatory cell accumulation.
The existence of a close link between oxidation and inflammation in the liver has been suggested previously (30). Immunochemical studies from our group showed that hepatic expressions of PON1 and monocyte chemoattractant protein-1 (MCP-1, a chemokine responsible for the recruitment of monocytes to the inflammatory areas) were increased in rats with CCl 4 -induced fibrosis, and the histological distribution was similar for both proteins (31). Moreover, hepatocytes were strongly stained for PON1 and MCP-1 when located in close proximity to inflammatory infiltrates and fibrosis septa. The present report adds more data in support of these conclusions.
In the current study, serum paraoxonase, arylesterse and DEPCyMCase activities were significantly decreased in HH patients. Changes in HDL structure and composition are known to influence PON1 activity because this enzyme is profoundly dependent on the lipid and protein compositional environment of the HDL particles for its activity (32). Since our HH patients had a reduced HDLcholesterol concentration but with normal apolipoprotein A-I levels, such a by guest, on March 11, 2013 www.jlr.org
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compositional change could explain our findings. Indeed, low HDL-cholesterol concentration is a common feature of chronic liver diseases (14, 15) , and has been associated with iron overload (33-35). Moreover, serum PON1 activity may be inhibited, additionally, by increased lipid peroxidation products in blood.
Lipid peroxides are well documented as having the ability to inhibit PON1 activity by reacting with the free sulfhydryl group at cysteine 284 (36) and, indeed, our patients had a marked increase in serum 8-isoprostane concentrations accompanying decreased PON1 activities. The consistent interrelationship between PON1 and oxidative stress was further emphasized in our study population by the observation that the statistical significant association between low PON1 activities and HH was lost following the inclusion of 8-isoprostanes in the regression model. This suggests an oxidative stress-related modulation of PON1 activities in HH.
Our results also show that the decrease in PON1 activity is related to serum ferritin concentration. High ferritin levels have been shown to be an important threshold that determines cirrhosis, and the risk of iron overload-associated death (37). These results are in agreement with previous observations in patients with other forms of liver disease in which a decreased serum PON1 activity was found to be associated with increased PON1 protein expression (13, 14) . Similar results were recently obtained in patients with coronary artery disease (38) . Previous studies showed that oxidized phospholipids and inflammatory cytokines decrease PON1 gene expression in hepatocyte cultures (39) (40) (41) . However, in vivo studies in rats with experimental cirrhosis showed that decreased serum PON1 activity was associated with increased PON1 protein (47), and cancer (48) . However, our results must be interpreted with caution since the numbers of HH patients were too low for a reliable genetic association study. Therefore, our conclusions need to be considered as preliminary and requiring confirmation in wider series of patients.
HH has a highly variable clinical and biochemical penetrance. Indeed, many patients do not develop severe iron overload or clinical symptoms and, hence, there is a growing interest in investigating the biological mechanisms and consequences of HH phenotypic heterogeneity (49, 50) . In a populationbased study (51) are tempted to speculate that PON1 may be a modifying factor of the HH phenotype. Future studies that prospectively address such issues are awaited.
In conclusion, the current study showed a significant decrease in serum PON1 activity, together with an increased hepatic PON1 protein expression in HH patients. Our data suggest that these alterations may play a role in the protection against iron-induced oxidative stress and its clinical consequences. 
